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To the Editor: Recently a new class of drugs, the
calcimimetic, which enhances calcium-sensing receptor
sensitivity in the parathyroid gland, has been introduced
and registered for the treatment of secondary hyperparathyr-
oidism for patients on dialysis.1,2 The drug name is cinacalcet
(Mimparas, Sensipars).
Patients treated with lithium sometimes develop hyper-
calcemia with or without hyperparathyroidism.3 This is
thought to be partially related to insensitivity of the calcium-
sensing receptor in the parathyroid gland induced by lithium
use,4 that is, a shift in the set-point for parathyroid hormone
secretion by calcium concentration.5 Surgical treatment is not
indicated for this hypercalcemia. Discontinuation of lithium
can be contraindicated owing to the severity of the
psychiatric illness.
After informed consent, we prescribed cinacalcet to three
patients with renal impairment (mean creatinine clearance
35 mmol/l) and chronic lithium use for depressive disorders
(discontinuation contraindicated), who had hypercalcemia
and/or hyperparathyroidism, which could only be attributed
to lithium use. Dosages required, guided by laboratory
results, ranged from 30 to 120 mg cinacalcet once daily.
The median serum calcium decreased from 2.72 mmol/l
(range: 2.64–2.89) to 2.52 mmol/l (range: 2.2–2.88), after
cinacalcet was titrated. The median serum phosphate
remained within the normal range from 1.16 mmol/l (range:
0.94–1.43) to 1.36 mmol/l (range: 0.82–1.68). Serum albumin
was normal during the complete follow-up (median 40 g/l).
The intact parathyroid hormone levels dropped from a
median value of 28.6 pmol/l (range: 11–52.3) to 11.0 pmol/l
(range: 9.1–32.7).
None of the patients developed side effects. All three
patients responded favorably to therapy with regards to either
hypercalcemia or hyperparathyroidism.
The observed response in these patients is compatible
with the hypothesis that cinacalcet ameliorates the lithium-
induced changes that lead to hypercalcemia and/or
hyperparathyroidism, that is, they neutralize their opposing
actions on the calcium-sensing receptor of the parathyroid
gland.
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